Focused On-demand Library for Solute carrier family 52, riboflavin transporter, member 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NQ40

UPID:

S52A3_HUMAN

Alternative names:

Riboflavin transporter 2

Alternative UPACC:

Q9NQ40; A0A2I6BQ49; A8K6P1; K0A6P4; Q5W1A0; Q5W1A1; Q8NCL7; Q96GD5

Background:

Solute carrier family 52, riboflavin transporter, member 3, also known as Riboflavin transporter 2, is crucial for cellular uptake of vitamin B2/riboflavin. This vitamin is essential for oxidation-reduction reactions in carbohydrate, lipid, and amino acid metabolism. Humans must absorb it through the intestine, as they cannot synthesize it.

Therapeutic significance:

Linked to Brown-Vialetto-Van Laere syndrome 1 and Fazio-Londe disease, this protein's dysfunction results in severe neurological disorders. Understanding its role could lead to novel treatments for these diseases.